FDA Drug Safety Communication: FDA to Evaluate Potential Risk of Neural Tube Birth Defects with HIV Medicine Dolutegravir
Source
FDA Drug Safety Communication: FDA to Evaluate Potential Risk of Neural Tube Birth Defects with HIV Medicine Dolutegravir